-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Raises Price Target to $33

Benzinga·11/05/2026 14:34:07
Listen to the news
Evercore ISI Group analyst Maneka Mirchandaney maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $26 to $33.